Cargando…

Preliminary association of circulating tumor cells (CTCs) pre- and post-AdHER2 dendritic cell vaccination with overall survival in patients with metastatic HER2+ solid tumors

Detalles Bibliográficos
Autores principales:	Tomita, Yusuke, Trepel, Jane, Lee, Min-Jung, Lee, Sunmin, Berzofsky, Jay A, Wood, Lauren V
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645504/ http://dx.doi.org/10.1186/2051-1426-3-S2-P179

Ejemplares similares

Detection of circulating tumor cells (CTCs) in cerebrospinal fluid of a patient with HER2-overexpressing gastric cancer and single cell analysis of intra-patient heterogeneity of CTCs
por: Cho, Jang Ho, et al.
Publicado: (2019)

Functional Characterization of Circulating Tumor Cells (CTCs) from Metastatic ER+/HER2− Breast Cancer Reveals Dependence on HER2 and FOXM1 for Endocrine Therapy Resistance and Tumor Cell Survival: Implications for Treatment of ER+/HER2− Breast Cancer
por: Roßwag, Sven, et al.
Publicado: (2021)

HER2 status of CTCs by peptide-functionalized nanoparticles as the diagnostic biomarker of breast cancer and predicting the efficacy of anti-HER2 treatment
por: Wang, Mengting, et al.
Publicado: (2022)

Single-Cells Isolation and Molecular Analysis: Focus on HER2-Low CTCs in Metastatic Breast Cancer
por: D’Amico, Paolo, et al.
Publicado: (2021)

Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
por: Fehm, Tanja, et al.
Publicado: (2007)

Peptide-induced mRNAs in whole blood ex vivo as a unique assay for peptide-specific T cell immunity
por: Mitsuhashi, Masato, et al.
Publicado: (2013)

Comparison of tumors with HER2 overexpression versus HER2 amplification in HER2-positive breast cancer patients
por: Horimoto, Yoshiya, et al.
Publicado: (2022)

Phase I Clinical Trial of an Autologous Dendritic Cell Vaccine Against HER2 Shows Safety and Preliminary Clinical Efficacy
por: Maeng, Hoyoung M., et al.
Publicado: (2021)

Single HER2-positive tumor cells are detected in initially HER2-negative breast carcinomas using the DEPArray™–HER2-FISH workflow
por: Grüntkemeier, Lisa, et al.
Publicado: (2022)

HER2-Positive Circulating Tumor Cells in Breast Cancer
por: Ignatiadis, Michail, et al.
Publicado: (2011)

Quantifying HER-2 expression on circulating tumor cells by ACCEPT
por: Zeune, Leonie, et al.
Publicado: (2017)

Circulating tumor cells (CTCs) and hTERT gene expression in CTCs for radiotherapy effect with lung cancer
por: Xu, Ying, et al.
Publicado: (2023)

SDPS-20 THE HER2 FLIP: HER2 AMPLIFICATION OF TUMOR CELLS IN THE CEREBROSPINAL FLUID (CSF-TCS) OF PATIENTS WITH LEPTOMENINGEAL METASTASIS HAVING SOLID TUMORS; IMPLICATIONS FOR TREATING THE LM TUMOR WITH ANTI-HER2 THERAPY
por: Kumthekar, Priya, et al.
Publicado: (2023)

Circulating tumor cells (CTCs) are associated with abnormalities in peripheral blood dendritic cells in patients with inflammatory breast cancer
por: Mego, Michal, et al.
Publicado: (2016)

An Ad5 [E1-, E2b-]-HER2/neu vector induces immune responses and inhibits HER2/neu expressing tumor progression in Ad5 immune mice
por: Gabitzsch, Elizabeth S., et al.
Publicado: (2011)

Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor()
por: Beije, Nick, et al.
Publicado: (2016)

Exosomes containing miRNAs targeting HER2 synthesis and engineered to adhere to HER2 on tumor cells surface exhibit enhanced antitumor activity
por: Wang, Lei, et al.
Publicado: (2020)

A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
por: Yang, Yuqin, et al.
Publicado: (2022)

Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells
por: Weiss, Vivian L., et al.
Publicado: (2012)

Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases
por: Bartsch, R, et al.
Publicado: (2012)

The Prognostic Role of Circulating Tumor Cells (CTCs) in Lung Cancer
por: Kapeleris, Joanna, et al.
Publicado: (2018)

Fugitives on the run: circulating tumor cells (CTCs) in metastatic diseases
por: Mamdouhi, Tania, et al.
Publicado: (2019)

Apoptotic circulating tumor cells (CTCs) in the peripheral blood of metastatic colorectal cancer patients are associated with liver metastasis but not CTCs
por: Allen, Joshua E., et al.
Publicado: (2013)

Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients
por: Zhang, Shaohua, et al.
Publicado: (2016)

Interaction of host immunity with HER2-targeted treatment and tumor heterogeneity in HER2-positive breast cancer
por: Griguolo, Gaia, et al.
Publicado: (2019)

Determining HER2 Status by Artificial Intelligence: An Investigation of Primary, Metastatic, and HER2 Low Breast Tumors
por: Palm, Christiane, et al.
Publicado: (2023)

HER2-low breast cancer: evolution of HER2 expression from primary tumor to distant metastases
por: Cai, Mengyuan, et al.
Publicado: (2023)

Luminal B breast tumors are not HER2 positive
por: Bhargava, Rohit, et al.
Publicado: (2008)

Dendritic Cells Pulsed with Cytokine-Adjuvanted Tumor Membrane Vesicles Inhibit Tumor Growth in HER2-Positive and Triple Negative Breast Cancer Models
por: Munoz, Luis E., et al.
Publicado: (2021)

Clinical characteristics, tumor‐infiltrating lymphocytes, and prognosis in HER2‐low breast cancer: A comparison study with HER2‐zero and HER2‐positive disease
por: Lu, Yujie, et al.
Publicado: (2023)

Using in vivo fluorescence lifetime imaging to detect HER2-positive tumors
por: Ardeshirpour, Yasaman, et al.
Publicado: (2018)

A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells
por: Yu, Shengnan, et al.
Publicado: (2019)

A novel anti-HER2 antibody GB235 reverses Trastuzumab resistance in HER2-expressing tumor cells in vitro and in vivo
por: Shu, Mengjun, et al.
Publicado: (2020)

Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trial
por: Jacot, William, et al.
Publicado: (2019)

Model-Based Analysis of HER Activation in Cells Co-Expressing EGFR, HER2 and HER3
por: Shankaran, Harish, et al.
Publicado: (2013)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
por: Lucci, Maria Antonietta, et al.
Publicado: (2010)

The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review
por: Mendes, Diogo, et al.
Publicado: (2015)

Breast Cancer With a HER2 IHC2+ and FISH HER2/CEP17 Ratio ≥2.0 and an Average HER2 Gene Copy Number <4.0 per Tumor Cell: HER2 mRNA Overexpression Is a Rare Event
por: Liu, Yuanyuan, et al.
Publicado: (2020)

Tumor regression is mediated via the induction of HER2(63-71)- specific CD8+ CTL activity in a 4T1.2/HER2 tumor model: no involvement of CD80 in tumor control
por: Danishmalik, Sayyed Nilofar, et al.
Publicado: (2017)

Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor
por: Hu, Zexi, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_fdovlu6bc2qp87scjbjtgm8q2m